Top-Rated StocksTop-RatedNASDAQ:IMVT Immunovant (IMVT) Stock Forecast, Price & News $38.39 -1.40 (-3.52%) (As of 09/29/2023 08:53 PM ET) Add Compare Share Share Today's Range$37.97▼$40.7450-Day Range$19.59▼$39.9652-Week Range$5.09▼$44.19Volume2.57 million shsAverage Volume1.35 million shsMarket Capitalization$5.02 billionP/E RatioN/ADividend YieldN/APrice Target$34.83 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Immunovant MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside9.3% Downside$34.83 Price TargetShort InterestBearish9.70% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.58Based on 45 Articles This WeekInsider TradingSelling Shares$6.46 M Sold Last QuarterProj. Earnings GrowthGrowingFrom ($1.91) to ($1.86) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.55 out of 5 starsMedical Sector895th out of 970 stocksBiological Products, Except Diagnostic Industry147th out of 156 stocks 2.5 Analyst's Opinion Consensus RatingImmunovant has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 12 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $34.83, Immunovant has a forecasted downside of 9.3% from its current price of $38.39.Amount of Analyst CoverageImmunovant has been the subject of 9 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 1.0 Short Interest Percentage of Shares Shorted9.70% of the float of Immunovant has been sold short.Short Interest Ratio / Days to CoverImmunovant has a short interest ratio ("days to cover") of 4.6.Change versus previous monthShort interest in Immunovant has recently increased by 4.69%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldImmunovant does not currently pay a dividend.Dividend GrowthImmunovant does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for IMVT. Previous Next 2.5 News and Social Media Coverage News SentimentImmunovant has a news sentiment score of 0.58. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.70 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 45 news articles for Immunovant this week, compared to 3 articles on an average week.Search Interest31 people have searched for IMVT on MarketBeat in the last 30 days. This is an increase of 182% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added Immunovant to their MarketBeat watchlist in the last 30 days. This is a decrease of -33% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Immunovant insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $6,457,305.00 in company stock.Percentage Held by InsidersOnly 4.80% of the stock of Immunovant is held by insiders.Percentage Held by Institutions42.45% of the stock of Immunovant is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Immunovant are expected to grow in the coming year, from ($1.91) to ($1.86) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Immunovant is -19.89, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Immunovant is -19.89, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioImmunovant has a P/B Ratio of 13.81. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Immunovant (NASDAQ:IMVT) StockImmunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of myasthenia gravis and thyroid eye disease, as well as completed initiation of Phase II clinical trials for the treatment of warm autoimmune hemolytic anemia. The company was incorporated in 2018 is headquartered in New York, New York. Immunovant, Inc. is a subsidiary of Roivant Sciences Ltd.Read More IMVT Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart IMVT Stock News HeadlinesOctober 2, 2023 | americanbankingnews.comEquities Analysts Set Expectations for Immunovant, Inc.'s Q1 2025 Earnings (NASDAQ:IMVT)October 1, 2023 | americanbankingnews.comImmunovant (NASDAQ:IMVT) Stock Price Down 4.4%October 2, 2023 | Behind the Markets (Ad)The World's First "$20 Trillion Drug?" One small biotech holds the key to a revolution in treating Alzheimer's disease. Jeff Bezos, Goldman Sachs & Big Pharma giants have invested billions into this unknown biotech. Our research proves that anyone who gets in today could see 113,000% gains! Get the name of the stock here >>>September 30, 2023 | americanbankingnews.comImmunovant (NASDAQ:IMVT) PT Raised to $48.00September 30, 2023 | americanbankingnews.comCitigroup Boosts Immunovant (NASDAQ:IMVT) Price Target to $50.00September 30, 2023 | americanbankingnews.comLeerink Partnrs Brokers Increase Earnings Estimates for Immunovant, Inc. (NASDAQ:IMVT)September 29, 2023 | msn.comCitigroup Maintains Immunovant (IMVT) Buy RecommendationSeptember 29, 2023 | americanbankingnews.comImmunovant (NASDAQ:IMVT) Sees Large Volume Increase Following Analyst UpgradeOctober 2, 2023 | Stansberry Research (Ad)U.S. "Shadow Banks" About to Blow up again?Analyst who called Lehman crash says our biggest calamities (1907, 1929, 2007, etc) all start in the same spot--and it’s about to happen again. More here.September 28, 2023 | finance.yahoo.comBiotech Stock Roundup: ICPT Up on Buyout Deal, IMVT & PLRX Gain on Study DataSeptember 28, 2023 | finance.yahoo.comImmunovant Announces Pricing of $450 Million Common Stock FinancingSeptember 28, 2023 | americanbankingnews.comImmunovant (NASDAQ:IMVT) Given New $48.00 Price Target at GuggenheimSeptember 28, 2023 | americanbankingnews.comImmunovant (NASDAQ:IMVT) Shares Gap Up on Analyst UpgradeSeptember 27, 2023 | msn.comRaymond James Upgrades Immunovant (IMVT)September 27, 2023 | finance.yahoo.comImmunovant Parlays Its Shot At Rivaling Argenx Into A $300 Million OfferingSeptember 27, 2023 | msn.comImmunovant stock rallies for second day, fueled by public offering, drug dataSeptember 27, 2023 | finance.yahoo.comImmunovant (IMVT) Soars on Upbeat Initial IMVT-1402 Study DataSeptember 27, 2023 | seekingalpha.comImmunovant: Immune Boost, From Clinical Trials To An Aggressive Bullish StockSeptember 27, 2023 | americanbankingnews.comTruist Financial Reiterates "Buy" Rating for Immunovant (NASDAQ:IMVT)September 27, 2023 | americanbankingnews.comRaymond James Upgrades Immunovant (NASDAQ:IMVT) to "Outperform"September 26, 2023 | msn.comImmunovant Shares Skyrocket After Trial of Its Autoimmune Drug Beats ExpectationsSeptember 26, 2023 | finance.yahoo.comWhy Shares of Immunovant Are Soaring on TuesdaySeptember 26, 2023 | finance.yahoo.comImmunovant Doubles — And Slugs Argenx — As Autoimmune Disease Battle Heats UpSeptember 26, 2023 | finance.yahoo.comImmunovant Announces Proposed Offering of $300 Million of Common StockSeptember 26, 2023 | ca.style.yahoo.comImmunovant shares surge as early antibody treatment data beats expectationsSeptember 26, 2023 | reuters.comImmunovant shares surge after antibody treatment succeeds in early-stage studySeptember 26, 2023 | markets.businessinsider.comImmunovant Stock Receives Buy Rating Following Promising Initial Results of ‘1402 Anti-FcRn TrialSee More Headlines Receive IMVT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Immunovant and its competitors with MarketBeat's FREE daily newsletter. Email Address IMVT Company Calendar Last Earnings8/10/2023Today10/02/2023Next Earnings (Estimated)11/03/2023Fiscal Year End3/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:IMVT CUSIPN/A CIK1764013 Webwww.immunovant.com Phone917-580-3099FaxN/AEmployees164Year FoundedN/APrice Target and Rating Average Stock Price Forecast$34.83 High Stock Price Forecast$50.00 Low Stock Price Forecast$21.00 Forecasted Upside/Downside-9.3%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage12 Analysts Profitability EPS (Most Recent Fiscal Year)($1.93) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-210,960,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-63.02% Return on Assets-56.54% Debt Debt-to-Equity RatioN/A Current Ratio6.82 Quick Ratio6.82 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$2.78 per share Price / Book13.81Miscellaneous Outstanding Shares130,670,000Free Float124,400,000Market Cap$5.02 billion OptionableNot Optionable Beta0.91 Investing Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free Report Key ExecutivesDr. Frank M. Torti M.B.A. (Age 44)M.D., MBA, Exec. Chairperson of the Board Comp: $92.5kDr. Peter Salzmann M.B.A. (Age 55)M.D., CEO & Director Comp: $1.02MMs. Eva Renee Barnett M.B.A. (Age 43)Chief Financial Officer Comp: $871.07kDr. William L. Macias M.D. (Age 65)Ph.D., Chief Medical Officer Comp: $719.88kDr. Jay S. Stout Ph.D. (Age 60)Chief Technology Officer Dr. Chau Cheng M.B.A.Ph.D., VP of Investor RelationsMr. Mark S. Levine (Age 50)Chief Legal Officer & Corp. Sec. Ms. Lauren Schrier M.B.A.VP of MarketingMs. Christine BlodgettVP of HRDr. Julia G. Butchko Ph.D. (Age 52)Chief Devel. Officer More ExecutivesKey CompetitorsAbcamNASDAQ:ABCMHalozyme TherapeuticsNASDAQ:HALOVaxcyteNASDAQ:PCVXCRISPR TherapeuticsNASDAQ:CRSPGinkgo BioworksNYSE:DNAView All CompetitorsInsiders & InstitutionsBarclays PLCBought 2,200 shares on 9/21/2023Ownership: 0.002%Peter SalzmannSold 56,774 sharesTotal: $1.25 M ($22.02/share)Perceptive Advisors LLCBought 1,231,925 shares on 8/24/2023Ownership: 1.931%Eva Renee BarnettSold 14,386 sharesTotal: $292,035.80 ($20.30/share)Mark S LevineSold 12,286 sharesTotal: $249,405.80 ($20.30/share)View All Insider TransactionsView All Institutional Transactions IMVT Stock - Frequently Asked Questions Should I buy or sell Immunovant stock right now? 12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Immunovant in the last year. There are currently 12 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" IMVT shares. View IMVT analyst ratings or view top-rated stocks. What is Immunovant's stock price forecast for 2023? 12 Wall Street analysts have issued 12-month target prices for Immunovant's shares. Their IMVT share price forecasts range from $21.00 to $50.00. On average, they expect the company's stock price to reach $34.83 in the next year. This suggests that the stock has a possible downside of 9.3%. View analysts price targets for IMVT or view top-rated stocks among Wall Street analysts. How have IMVT shares performed in 2023? Immunovant's stock was trading at $17.75 at the start of the year. Since then, IMVT shares have increased by 116.3% and is now trading at $38.39. View the best growth stocks for 2023 here. When is Immunovant's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Friday, November 3rd 2023. View our IMVT earnings forecast. How were Immunovant's earnings last quarter? Immunovant, Inc. (NASDAQ:IMVT) issued its earnings results on Thursday, August, 10th. The company reported ($0.47) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.44) by $0.03. What ETFs hold Immunovant's stock? ETFs with the largest weight of Immunovant (NASDAQ:IMVT) stock in their portfolio include ALPS Medical Breakthroughs ETF (SBIO), Alpha Architect U.S. Quantitative Momentum ETF (QMOM), Virtus LifeSci Biotech Clinical Trials ETF (BBC) and Principal Healthcare Innovators ETF (BTEC).IQ U.S. Small Cap ETF (CSML). What other stocks do shareholders of Immunovant own? Based on aggregate information from My MarketBeat watchlists, some companies that other Immunovant investors own include Salesforce (CRM), NVIDIA (NVDA), Advanced Micro Devices (AMD), Walt Disney (DIS), Fulcrum Therapeutics (FULC), Myovant Sciences (MYOV), Alibaba Group (BABA), Inovio Pharmaceuticals (INO), JD.com (JD) and Johnson & Johnson (JNJ). What is Immunovant's stock symbol? Immunovant trades on the NASDAQ under the ticker symbol "IMVT." How do I buy shares of Immunovant? Shares of IMVT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Immunovant's stock price today? One share of IMVT stock can currently be purchased for approximately $38.39. How much money does Immunovant make? Immunovant (NASDAQ:IMVT) has a market capitalization of $5.02 billion. The company earns $-210,960,000.00 in net income (profit) each year or ($1.93) on an earnings per share basis. How many employees does Immunovant have? The company employs 164 workers across the globe. How can I contact Immunovant? Immunovant's mailing address is 320 WEST 37TH STREET, NEW YORK NY, 10018. The official website for the company is www.immunovant.com. The company can be reached via phone at 917-580-3099 or via email at info@immunovant.com. This page (NASDAQ:IMVT) was last updated on 10/2/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Immunovant, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.